Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05 Janvier 2024 - 10:05PM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
oncology company developing first-in-class1 therapeutics that
combine both targeted and immune-mediated mechanisms, today
announced that on January 3, 2024 the Compensation Committee of the
Company’s Board of Directors granted one employee a nonqualified
stock option to purchase 4,500 shares of its common stock under the
Company’s 2023 Inducement Plan. The stock option will vest over a
four-year period, with 25% of the option vesting on the first
anniversary of the employee’s start date, and 1/48th of the total
shares vesting monthly thereafter, subject to continued employment
on each vesting date.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
oncology company advancing small molecules that combine both
tumor-targeted and immune-mediated mechanisms with the potential to
treat a wide range of tumors. The company has a diverse portfolio
of novel programs ranging from early research to investigation in a
randomized global study in first-line cancer patients. The
company’s two novel clinical programs, TPST-1120 and TPST-1495,
target PPARα and EP2/EP4, respectively, and are advancing through
trials designed to study the agents as monotherapies and in
combination with approved agents. Tempest is also developing an
orally available inhibitor of TREX1, a target that controls
activation of the cGAS/STING pathway. Tempest is headquartered in
Brisbane, California. More information about Tempest can be found
on the company’s website at www.tempesttx.com.
Investor Contacts:
Sylvia WheelerWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Aljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
1 If approved by the FDA
Tempest Therpeutics (NASDAQ:TPST)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Tempest Therpeutics (NASDAQ:TPST)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024